European Journal of Cancer · 2022 · 14 citations · 12 references
MedicineOncologyPharmacologyCancer ImmunologyCancer PharmacologyImmunoregulationCancer ImmunotherapyLung CancerLung Cancer PharmacotherapyMalignant NeoplasmsTumor Immune MicroenvironmentTumor Microenvironment ModulationImmune Effector FunctionsMalignant Pleural Mesothelioma ImmunotherapySmall Cell Lung Cancer ImmunotherapySmall Cell Lung Cancer TherapySmall Cell Lung Cancer Treatment
Purpose: Lurbinectedin is a promising new drug being investigated in pre-treated patients with small cell lung cancer (SCLC) or malignant pleural mesothelioma (MPM). Its clinical activity in the real-world setting has not been investigated yet. Patients and methods: Clinical data of patients with SCLC and MPM who were treated with lurbinectedin were prospectively collected. Comprehensive immune cell profiling by flow cytometry was performed on screening and treating peripheral blood samples. Results: A total of 95 patients (43 SCLC and 52 MPM) were treated, mostly as !3-line of therapy. In the SCLC cohort, a median progression-free survival (mPFS) was 1.5 months (95% CI: 1.4e3.0), and median overall survival was 7.0 months (95% CI: 4.7enot reached). Objective radiological response and disease control rate after 12 weeks were 16% and 28%, respectively. In the MPM cohort, median progression-free survival was 2.8 months (95% CI: 1.4e4.2), and median overall survival was 7.2 months (95% CI: 5.9enot reached). Disease control rate after 12 weeks was 29%, whereas no partial responses were registered. No new safety signals were
12
Stephen V. Liu, Martin Reck, Aaron S. Mansfield et al. · Journal of Clinical Oncology · 2021 · 824 citations · Full text
Medicine, Oncology, Pharmacology +16
Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text
Medicine, Oncology, Pharmacology +14
Gema Santamaría Núñez, Carlos Mario Genes Robles, Christophe Giraudon et al. · Molecular Cancer Therapeutics · 2016 · 153 citations